By William Aird
Patients without antiphospholipid syndrome should receive a DOAC. DOACs are preferred over vitamin K antagonists such as warfarin/coumadin.
From the 2019 ASH guideline:
2021 ACCP clinical guideline recommendations:
If you are interested in getting the latest articles from The Blood Project, enter your name and email